Back to top
more

Ovid Therapeutics (OVID)

(Real Time Quote from BATS)

$0.48 USD

0.48
100,976

-0.02 (-3.28%)

Updated Aug 6, 2025 10:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 0% and 96.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of 128.57% and 6.79%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 24.09% and 9.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of -62.75% and 8.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 13.70% and 14.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Incyte (INCY) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 14.85% and 4.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 18.75% and 45.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of -4.17% and 1.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 14.86% and 0.14%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -50.95% and 35.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

by Zacks Equity Research

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 154.55% and 20.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -11.11% and 72.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -4% and 35.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 72.37% and 38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News

by Zacks Equity Research

Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.

Zacks Equity Research

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

by Zacks Equity Research

Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.

Zacks Equity Research

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 26.09% and 40.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -200% and 2.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 60% and 6.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Beam Therapeutics (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ovid Therapeutics (OVID) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 25% and 99.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?